Which has preferable earnings & valuation, CV or HSDT?

CapsoVision has higher revenue and earnings than Solana. CapsoVision is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 26.84 -$25.32M -$2.34 N/A Solana $9.59M 10.90 -$40.89M -$109.67 N/A

Is CV or HSDT more profitable?

CapsoVision has a net margin of -198.87% compared to Solana's net margin of -1,427.15%. CapsoVision's return on equity of 0.00% beat Solana's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Solana -1,427.15% -67.57% -24.09%

Does the media prefer CV or HSDT?

In the previous week, Solana had 1 more articles in the media than CapsoVision. MarketBeat recorded 5 mentions for Solana and 4 mentions for CapsoVision. Solana's average media sentiment score of 0.97 beat CapsoVision's score of 0.93 indicating that Solana is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solana 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, HSDT or ELMD?

Electromed has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solana $9.59M 10.90 -$40.89M -$109.67 N/A Electromed $71.75M 5.24 $5.15M $1.17 38.83

Is HSDT or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Solana's net margin of -1,427.15%. Electromed's return on equity of 15.71% beat Solana's return on equity. Company Net Margins Return on Equity Return on Assets Solana -1,427.15% -67.57% -24.09% Electromed 11.34% 15.71% 13.37%

Which has preferable valuation & earnings, SGHT or HSDT?

Sight Sciences has higher revenue and earnings than Solana. Sight Sciences is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 3.83 -$38.43M -$0.71 N/A Solana $9.59M 10.90 -$40.89M -$109.67 N/A

Is SGHT or HSDT more profitable?

Sight Sciences has a net margin of -46.83% compared to Solana's net margin of -1,427.15%. Sight Sciences' return on equity of -52.34% beat Solana's return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% Solana -1,427.15% -67.57% -24.09%

Does the media prefer HSDT or TMCI?

In the previous week, Solana had 4 more articles in the media than Treace Medical Concepts. MarketBeat recorded 5 mentions for Solana and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.24 beat Solana's score of 0.97 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solana 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Treace Medical Concepts 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, HSDT or CARL?

Carlsmed has higher revenue and earnings than Solana. Carlsmed is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solana $9.59M 10.90 -$40.89M -$109.67 N/A Carlsmed $50.51M 6.10 -$29.63M -$2.51 N/A

Is HSDT or CARL more profitable?

Carlsmed has a net margin of -57.76% compared to Solana's net margin of -1,427.15%. Carlsmed's return on equity of -60.74% beat Solana's return on equity. Company Net Margins Return on Equity Return on Assets Solana -1,427.15% -67.57% -24.09% Carlsmed -57.76% -60.74% -29.84%

Does the media refer more to HSDT or CARL?

In the previous week, Solana had 3 more articles in the media than Carlsmed. MarketBeat recorded 5 mentions for Solana and 2 mentions for Carlsmed. Solana's average media sentiment score of 0.97 beat Carlsmed's score of 0.96 indicating that Solana is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solana 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Carlsmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solana (HSDT) Competitors

$1.79 +0.05 (+2.87%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.01 (+0.56%)

As of 07/2/2026 07:57 PM Eastern

Compare

HSDT vs. CV, ELMD, SGHT, TMCI, and CARL

Should you buy Solana stock or one of its competitors? MarketBeat compares Solana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solana include CapsoVision (CV), Electromed (ELMD), Sight Sciences (SGHT), Treace Medical Concepts (TMCI), and Carlsmed (CARL). These companies are all part of the "medical equipment" industry.

How does Solana compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Solana (NASDAQ:HSDT) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

CapsoVision presently has a consensus target price of $8.50, suggesting a potential upside of 16.76%. Solana has a consensus target price of $3.50, suggesting a potential upside of 95.53%. Given Solana's higher probable upside, analysts clearly believe Solana is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CapsoVision has higher revenue and earnings than Solana. CapsoVision is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	26.84	-$25.32M	-$2.34	N/A
Solana	$9.59M	10.90	-$40.89M	-$109.67	N/A

18.6% of Solana shares are held by institutional investors. 2.3% of CapsoVision shares are held by company insiders. Comparatively, 14.4% of Solana shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Solana had 1 more articles in the media than CapsoVision. MarketBeat recorded 5 mentions for Solana and 4 mentions for CapsoVision. Solana's average media sentiment score of 0.97 beat CapsoVision's score of 0.93 indicating that Solana is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solana	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CapsoVision has a net margin of -198.87% compared to Solana's net margin of -1,427.15%. CapsoVision's return on equity of 0.00% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Solana	-1,427.15%	-67.57%	-24.09%

Summary

Solana beats CapsoVision on 7 of the 13 factors compared between the two stocks.

How does Solana compare to Electromed?

Solana (NASDAQ:HSDT) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Solana has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Electromed has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Electromed has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$9.59M	10.90	-$40.89M	-$109.67	N/A
Electromed	$71.75M	5.24	$5.15M	$1.17	38.83

Solana currently has a consensus target price of $3.50, suggesting a potential upside of 95.53%. Electromed has a consensus target price of $37.50, suggesting a potential downside of 17.46%. Given Solana's higher possible upside, equities analysts clearly believe Solana is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

In the previous week, Solana had 5 more articles in the media than Electromed. MarketBeat recorded 5 mentions for Solana and 0 mentions for Electromed. Solana's average media sentiment score of 0.97 beat Electromed's score of 0.00 indicating that Solana is being referred to more favorably in the media.

Company	Overall Sentiment
Solana	Positive
Electromed	Neutral

Electromed has a net margin of 11.34% compared to Solana's net margin of -1,427.15%. Electromed's return on equity of 15.71% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Electromed	11.34%	15.71%	13.37%

18.6% of Solana shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Comparatively, 10.5% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Electromed beats Solana on 10 of the 16 factors compared between the two stocks.

How does Solana compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Sight Sciences presently has a consensus price target of $8.14, indicating a potential upside of 49.43%. Solana has a consensus price target of $3.50, indicating a potential upside of 95.53%. Given Solana's stronger consensus rating and higher probable upside, analysts plainly believe Solana is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 18.6% of Solana shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by insiders. Comparatively, 14.4% of Solana shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sight Sciences has higher revenue and earnings than Solana. Sight Sciences is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.83	-$38.43M	-$0.71	N/A
Solana	$9.59M	10.90	-$40.89M	-$109.67	N/A

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Solana has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Solana had 5 more articles in the media than Sight Sciences. MarketBeat recorded 5 mentions for Solana and 0 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.87 beat Solana's score of 0.97 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sight Sciences	Very Positive
Solana	Positive

Sight Sciences has a net margin of -46.83% compared to Solana's net margin of -1,427.15%. Sight Sciences' return on equity of -52.34% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Solana	-1,427.15%	-67.57%	-24.09%

Summary

Sight Sciences beats Solana on 10 of the 17 factors compared between the two stocks.

How does Solana compare to Treace Medical Concepts?

Solana (NASDAQ:HSDT) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Solana has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

In the previous week, Solana had 4 more articles in the media than Treace Medical Concepts. MarketBeat recorded 5 mentions for Solana and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.24 beat Solana's score of 0.97 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Treace Medical Concepts	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solana has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$9.59M	10.90	-$40.89M	-$109.67	N/A
Treace Medical Concepts	$212.69M	1.28	-$59M	-$0.97	N/A

Treace Medical Concepts has a net margin of -29.44% compared to Solana's net margin of -1,427.15%. Treace Medical Concepts' return on equity of -67.04% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

Solana presently has a consensus target price of $3.50, suggesting a potential upside of 95.53%. Treace Medical Concepts has a consensus target price of $4.77, suggesting a potential upside of 13.30%. Given Solana's stronger consensus rating and higher probable upside, research analysts plainly believe Solana is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

18.6% of Solana shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 14.4% of Solana shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Solana and Treace Medical Concepts tied by winning 8 of the 16 factors compared between the two stocks.

How does Solana compare to Carlsmed?

Solana (NASDAQ:HSDT) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Solana presently has a consensus price target of $3.50, suggesting a potential upside of 95.53%. Carlsmed has a consensus price target of $18.75, suggesting a potential upside of 65.34%. Given Solana's higher possible upside, research analysts plainly believe Solana is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Solana had 3 more articles in the media than Carlsmed. MarketBeat recorded 5 mentions for Solana and 2 mentions for Carlsmed. Solana's average media sentiment score of 0.97 beat Carlsmed's score of 0.96 indicating that Solana is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Carlsmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.6% of Solana shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Carlsmed has a net margin of -57.76% compared to Solana's net margin of -1,427.15%. Carlsmed's return on equity of -60.74% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Carlsmed	-57.76%	-60.74%	-29.84%

Carlsmed has higher revenue and earnings than Solana. Carlsmed is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$9.59M	10.90	-$40.89M	-$109.67	N/A
Carlsmed	$50.51M	6.10	-$29.63M	-$2.51	N/A

Summary

Solana beats Carlsmed on 9 of the 15 factors compared between the two stocks.

Get Solana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSDT vs. The Competition

Export

Metric	Solana	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$101.59M	$7.35B	$6.82B	$12.56B
Dividend Yield	N/A	1.29%	2.68%	6.64%
P/E Ratio	-0.02	51.06	27.94	24.55
Price / Sales	10.90	84.16	533.34	97.27
Price / Cash	N/A	26.18	48.59	58.15
Price / Book	0.26	7.50	10.91	6.45
Net Income	-$40.89M	$159.19M	$3.57B	$336.71M
7 Day Performance	3.47%	-0.35%	2.19%	1.37%
1 Month Performance	20.95%	-1.15%	4.55%	1.67%
1 Year Performance	-81.02%	3.22%	33.42%	24.05%

Solana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSDT Solana	3.9702 of 5 stars	$1.79 +2.9%	$3.50 +95.5%	-81.7%	$101.59M	$9.59M	N/A	30	Gap Up
CV CapsoVision	1.332 of 5 stars	$6.50 +0.3%	$8.50 +30.8%	N/A	$324.77M	$13.56M	N/A	90	News Coverage
ELMD Electromed	0.5914 of 5 stars	$38.53 +0.3%	$37.50 -2.7%	+123.6%	$319.03M	$71.75M	51.37	160
SGHT Sight Sciences	3.7306 of 5 stars	$5.41 +3.2%	$8.14 +50.5%	+31.0%	$294.36M	$77.36M	N/A	210	Positive News
TMCI Treace Medical Concepts	2.4177 of 5 stars	$4.49 +12.0%	$4.77 +6.2%	-30.9%	$291.27M	$212.69M	N/A	250	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSDT) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solana (HSDT) Competitors